Your shopping cart is empty

Subscriber login

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Lilly Replenishing Pipeline With Biologics After Blockbuster Losses

Drug Industry Daily

Jan. 6, 2012 | Vol. 11 No. 4

Lilly Replenishing Pipeline With Biologics After Blockbuster Losses

Eli Lilly appears to be looking to biologics to replace several blockbuster drugs coming off patent as roughly half of its 20 Phase II products are biologics, the company says.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

AstraZeneca Buy of Heart Drug-Maker AlphaCore May Provide Needed R&D Perk Momenta Betting Biosimilar Push Will Put Balance Sheet Back in the Black Promising Pipeline, Pink Slips Boost Lilly’s 2013 Prospects: Analysts Pipeline Woes Strike Sanofi, Ipsen, Eisai: Nixed Applications, Clinical Holds and Trial Failures

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.